| Market Capitalization (Millions $) |
43 |
| Shares
Outstanding (Millions) |
9 |
| Employees |
17 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-14 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Edesa Biotech Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic treatments for dermatological and gastrointestinal diseases. The company is dedicated to addressing unmet medical needs and improving patient outcomes in these areas.
Edesa Biotech utilizes its proprietary approach to identify and develop small molecules that target specific biological pathways involved in disease pathogenesis. The company's lead product candidate is EB01, a novel non-steroidal, anti-inflammatory cream being developed for the treatment of chronic allergic contact dermatitis.
By leveraging its deep understanding of the underlying disease mechanisms and the potential therapeutic targets, Edesa Biotech aims to develop safe and effective treatments with improved efficacy compared to existing therapies. The company is committed to conducting rigorous clinical trials to evaluate the safety and efficacy profiles of its products.
Edesa Biotech also actively pursues collaborations and partnerships with other pharmaceutical companies and academic institutions to further enhance its drug development capabilities. The company is headquartered in Markham, Ontario, Canada, and primarily operates in North America.
Company Address: 100 Spy Court Markham 0
Company Phone Number: 800-9600 Stock Exchange / Ticker: NASDAQ EDSA
|
2.68% 